GlassScriptPhysician profile
Anayda Chavez
NPI 1306533252
$1,935.83
in general payments reported to CMS, 2019-2025
14 companies · $604 in 2025
The $604 reported for 2025 was more than what 78% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $503 · 2024: $704 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,810.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $545.57 | 2023-2025 | Epclusa, Livdelzi, Vemlidy |
| Abbott Laboratories | $145.89 | 2025 | Proclaim |
| Inspire Medical Systems, INC. | $132.34 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $125.04 | 2022 | |
| Abbvie INC. | $124.98 | 2024 | |
| Journey Medical Corporation | $123.69 | 2025 | |
| Kyowa Kirin, INC. | $123.16 | 2024 | |
| Genzyme Corporation | $119.02 | 2023 | |
| Incyte Corporation | $116.35 | 2025 | Opzelura |
| Alexion Pharmaceuticals, INC. | $98.44 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
| Coloplast Corp | $53.81 | 2023 | Titan, Altis |
| Medtronic, INC. | $37.82 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anayda Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.